Wire · regulatory
As politicians argue about China, US patients find cutting-edge treatment there
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 October 2026 · Fusion42 review
Chinese biotech has become a global leader in novel cancer therapies, attracting patients and clinical trials from the US and beyond, while US regulatory delays push drug development overseas. The FDA is attempting to accelerate approvals and reduce reliance on foreign drugs amid political concerns about Chinese influence in biotech.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 20 Oct 2026 and 23 Oct 2026.
◆ ◆ The Wire takeaway
Your US biotech startup faces faster foreign competitors and political hurdles. Act now to explore alternative trial locations like China or Australia to speed development or prepare for regulatory tightening on foreign partnerships.
◆ Coverage
3 sources · first reported 20 Oct 2026 · latest 23 Oct 2026
◆ Related on Wire
◆ Topics